openPR Logo
Press release

Deadline in Lawsuit for Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) on March 16th coming up

02-20-2020 04:05 PM CET | Politics, Law & Society

Press release from: Shareholders Foundation

A Deadline is coming up on March 16, 2020 in the lawsuit for certain investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA).

A Deadline is coming up on March 16, 2020 in the lawsuit for certain investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA).

The Shareholders Foundation announced that a deadline is coming up on March 16, 2020in the lawsuit filed for certain investors of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) over alleged securities laws violations by Portola Pharmaceuticals, Inc.

Investors who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and there are strict and short deadlines running. Deadline: March 16, 2020. NASDAQ: PTLA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) common shares between November 5, 2019 and January 9, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 5, 2019 and January 9, 2020, the Defendants failed to disclose to investors that Portola's internal control over financial reporting regarding reserve for product returns was not effective, that Portola was shipping longer-dated product with 36-month shelf life, that Portola had not established adequate reserve for returns of prior shipments of short-dated product, that, as a result, Portola was reasonably likely to need to "catch up" on accounting for return reserves, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline in Lawsuit for Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) on March 16th coming up here

News-ID: 1939839 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Portola

Oral Anticoagulant Market to Witness Huge Growth by 2030 | Bayer, Boehringer Ing …
HTF MI recently introduced Global Oral Anticoagulant Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market size (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence. Major Companies in Oral Anticoagulant Market are: Bristol-Myers Squibb, Pfizer, Johnson & Johnson, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Portola Pharmaceuticals, Sanofi, Aspen Pharmacare,
Apixaban Market Overall Study Report 2025-2032 | Bristol-Myers Squibb, Portola P …
The latest report, titled "Apixaban Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032" by Coherent Market Insights, offers an in-depth analysis of the industry, providing valuable insights into market dynamics. The study perhaps a perfect mixture of qualitative and quantitative information highlighting key market developments, challenges, competition industry face alongside gap analysis and new opportunities available and trend within the Apixaban Market. This report offers Market size, recent
Apixaban Market Determine a Spectacular Expansion And Productive Impact 2022-202 …
𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 released a new market study on 2022-2028 Apixaban Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The global research report delivers an in-depth watch on leading competitors with strategic analysis, small and macro business trends and eventualities, valuation analysis and a holistic summary within the forecast amount. Its knowledge and in-depth reports specializing in primary
Investigation for Long-Term Investors in shares of Portola Pharmaceuticals, Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Portola Pharmaceuticals, Inc.. Investors who are current long term investors in Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: PTLA stocks follows a lawsuit filed against Portola
Lawsuit filed for Investors in shares of Portola Pharmaceuticals, Inc. (NASDAQ: …
An investor, who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), filed a lawsuit over alleged Securities Laws violations by Portola Pharmaceuticals, Inc.. Investors who purchased shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: March 16, 2020. NASDAQ: PTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. San Francisco, CA based Portola Pharmaceuticals,
Apixaban Market is Booming 2019 | Pfizer, Roche, CoaguSense, Siemens, Alere, Abb …
Apixaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market as capsules and tablet form. Increasing prevalence of venous thromboembolism related conditions is expected to aid in growth of the apixaban market. For instance, according to International Society on Thrombosis and Haemostasis 2014 facts, revealed that